The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Chromatin modifications are essential for directing transcription during embryonic development. Bromodomain-containing protein 2 (Brd2; also called RING3 and Fsrg1) is one of four BET (bromodomain and extra terminal domain) family members known to selectively bind acetylated histones H3 and H4. Brd2 associates with multiple subunits of the transcriptional apparatus including the mediator, TFIID and Swi/Snf multi-protein complexes. While molecular interactions of Brd2 are known, the functions of Brd2 in mammalian embryogenesis remain unknown. In developing a mouse model deficient in Brd2, we find that Brd2 is required for the completion of embryogenesis and proper neural tube closure during development. Embryos lacking Brd2 expression survive up to embryonic day 13.5, soon after mid-gestation, and display fully penetrant neurulation defects that largely result in exencephaly of the developing hindbrain. In this study, we find that highest expression of Brd2 is detected in the developing neural tube, correlating with the neural tube defects found in Brd2-null embryos. Additionally, embryos lacking Brd2 expression display altered gene expression programs, including the mis-expression of multiple genes known to guide neuronal development. Together these results implicate essential roles for Brd2 as a critical integrator of chromatin structure and transcription during mammalian embryogenesis and neurogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732
Houzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., & Beddington, R. S. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3794-3802.2002 · Cited by 318 · cited 2×
“Disruption of the Brd2-related paralog, Brd4, in the mouse leads to early post-implantation lethality in vivo and an inability to maintain the inner cell mass in vitro [21].”
Coordinate regulation of neural tube patterning and proliferation by TGFβ and WNT activity
Chesnutt, C., Burrus, L. W., Brown, A. M. C., & Niswander, L. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.07.019 · Cited by 152
Cited by
BET domain co-regulators in obesity, inflammation and cancer
Belkina, A. C., & Denis, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3256 · Cited by 711
Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., & Howley, P. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01341-10 · Cited by 532
“Knockout of Brd4 or Brd2 in mice results in early embryonic lethality (18, 21).”
BackgroundWegner, N., Lundberg, K., Kinloch, A., Fisher, B., Malmström, V., Feldmann, M., & Venables, P. J. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2009.00850.x · Cited by 471
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Chromatin proteins and modifications as drug targets
Helin, K., & Dhanak, D. (2013) · Nature · doi:10.1038/nature12751 · Cited by 427
Belkina, A. C., Nikolajczyk, B. S., & Denis, G. V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202838 · Cited by 418
Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
Liu, W., Ma, Q., Wong, K., Li, W., Ohgi, K., Zhang, J., Aggarwal, A. K., & Rosenfeld, M. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.056 · Cited by 406
Taniguchi, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111849 · Cited by 336
Harris, M. J., & Juriloff, D. M. (2010) · Birth Defects Research Part A: Clinical and Molecular Teratology · doi:10.1002/bdra.20676 · Cited by 335
Brd2 disruption in mice causes severe obesity without Type 2 diabetes
Wang, F., Liu, H., Blanton, W. P., Belkina, A., Lebrasseur, N. K., & Denis, G. V. (2010) · Biochemical Journal · doi:10.1042/bj20090928 · Cited by 185
“Consistent with this expectation, we could not obtain brd2(−/−)-null mice or ES (embryonic stem) cells, and in support of this result, recent reports have established that Brd2 is essential because brd2(−/−)null mice have neural tube defects and embryonic lethality [33,34].”
BackgroundResultSmall molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Jiang, D., Li, T., Guo, C., Tang, T.-S., & Liu, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00953-4 · Cited by 54
Metadata
- Authors
- Gyuris, A., Donovan, D. J., Seymour, K. A., Lovasco, L. A., Smilowitz, N. R., Halperin, A. L. P., Klysik, J. E., & Freiman, R. N.
- Venue
- Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 1789
- Issue
- 5
- Pages
- 413-421
- ISSN
- 1874-9399 (ISSN-L)
- OpenAlex
- W1990634533
- Cited by
- 102
- References
- 3
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.